<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2110">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787588</url>
  </required_header>
  <id_info>
    <org_study_id>11033-T</org_study_id>
    <nct_id>NCT04787588</nct_id>
  </id_info>
  <brief_title>COVID-19 Infection and Epithelial Cell Markers</brief_title>
  <official_title>COVID-19 Infection and Epithelial Cell Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if TSLP expression by airway epithelial cells following COVID-19 infection&#xD;
      regulates viral load and disease severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aim is to determine the relationship between COVID-19 infection and epithelial cell&#xD;
      expression of TSLP. Two cohorts will be used. Cohort One will include 100 hospitalized&#xD;
      patients with Covid-19, and 100 hospitalized patients without Covid-19. Cohort 2 will include&#xD;
      mild/moderate asthmatics and healthy controls with bio-banked biopsy material used from&#xD;
      donors who have previously consented for samples to be used for future research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TSLP expression in nasal epithelium</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Compare the level of TSLP expression in nasal epithelium in patients with and without COVID-19 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TSLP expression in endobronchial biopsies</measure>
    <time_frame>Baseline</time_frame>
    <description>Epithelial cell expression (protein staining) of TSLP in endobronchial biopsy tissue of asthmatic patients versus normal controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-33 expression in endobronchial biopsies</measure>
    <time_frame>Baseline</time_frame>
    <description>Epithelial cell expression (protein staining) of IL-33 in endobronchial biopsy tissue of asthmatic patients versus normal controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACE-2 receptor expression in endobronchial biopsies</measure>
    <time_frame>Baseline</time_frame>
    <description>Epithelial cell expression (protein staining) of ACE-2 receptor in endobronchial biopsy tissue of asthmatic patients versus normal controls.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Asthma</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Hospitalized patients</arm_group_label>
    <description>100 patients hospitalized with Covid-19, and 100 hospitalized controls without Covid-19</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild/Moderate asthma and health controls</arm_group_label>
    <description>20 asthmatic patients, 10 patients with asthma and allergic rhinitis, and 5 healthy controls.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood TSLP levels will be measured and SNP genotyping for alarmins will be performed from&#xD;
      Cohort 1 patients&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and above;&#xD;
&#xD;
          -  Able to give informed consent;&#xD;
&#xD;
          -  Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g.&#xD;
             RT-PCR) and with a positive result and clinical features in keeping with COVID-19&#xD;
             illness. The control group will be patients with a negative RT-PCR COVID-19 test and&#xD;
             without any clinical features to suggest COVID-19 illness. In addition, the control&#xD;
             group should have NO known or current features of respiratory infection, COPD, asthma,&#xD;
             interstitial lung disease, other respiratory inflammatory conditions or lung cancer.&#xD;
&#xD;
          -  Able to provide a breath sample (as based on clinical judgement).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Gauvreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail Gauvreau, PhD</last_name>
    <phone>9055259140</phone>
    <phone_ext>22791</phone_ext>
    <email>gauvreau@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>McMaster Cardio-Respiratory Research Lab</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Gauvreau, PhD</last_name>
      <phone>9055259140</phone>
      <phone_ext>22600</phone_ext>
      <email>gauvreau@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <phone>9055259140</phone>
      <phone_ext>22791</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Gail Gauvreau, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Gail Gauvreau</investigator_full_name>
    <investigator_title>Professor Department of MEdicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

